{"disease":{"id":"brca-mutated-breast-cancer","name":"brca mutated breast cancer"},"drugs":{"marketed":[{"drug_id":"atezolizumab","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"talazoparib-tosylate","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"talazoparib-tosylate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP1, PARP2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":75,"revenue":"182","mechanism":"Talazoparib inhibits PARP enzymes, causing DNA damage and cell death in cancer cells with DNA repair defects."},{"drug_id":"talzenna","indication_name":"BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"talazoparib","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"talazoparib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 4","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":72,"revenue":"182","mechanism":"Talzenna blocks PARP enzymes, which are involved in DNA repair, to prevent cancer cell growth."},{"drug_id":"alpelisib","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piqray","generic_name":"alpelisib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"PI3Kα","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Alpelisib inhibits PI3Kα, blocking Akt-signaling and preventing tumor growth and organ abnormalities in PROS disorders."}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Advanced BRCA-mutated or HDR-deficient breast cancer","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."}],"offLabel":[],"totalMarketed":5,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05576389","title":"Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":94,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT01853306","title":"A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT06065059","title":"Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Tango Therapeutics, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}